Skip to main content
SpringerLink
Log in

Immunotherapy for Autoimmune Diseases

  • Chapter
  • First Online:
Immunotherapy – A Novel Facet of Modern Therapeutics

  • 691 Accesses

Abstract

Various pathologies caused by a dysregulated immune system characterized by chronic inflammation leading to pain or permanent damage to tissue are grouped under an umbrella term “autoimmune disorders.” Immunotherapy is a field of immunology that facilitates discovery of therapies for diseases by means of stimulation, augmentation, or suppression of an immunoresponse. Several emerging and promising next-generation immunotherapy modalities for autoimmune diseases such as checkpoint based immunotherapy, antigen-specific immunotherapies, anti-cytokine therapy, anti-T-cell therapy, anti-B-cell therapy and biologics and their combination therapy, etc., have evolved and initiated the new era of immunotherapy for autoimmune diseases in the recent past. We discuss these modalities in detail along with comprehensive tables that elucidate the specific therapies. Further, we delineate current immunotherapeutics in clinical trials for autoimmune diseases and discuss the “financial toxicity” of current immunotherapies in autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agius M, Klodowska-Duda G, Maciejowski M, Potemkowski A, Sweeny S, Li J et al (2015) Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler 23(11):235–236

    Google Scholar 

  • Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N et al (2017) Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ 20(9):982–990

    Article  PubMed  Google Scholar 

  • Anandarajah AP, Luc M, Ritchlin CT (2017) Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs. Lupus 26(7):756–761

    Article  CAS  PubMed  Google Scholar 

  • Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AANS (2014) Modern anti-cytokine therapy of autoimmune diseases. Biochemist 79(12):1308–1321

    CAS  Google Scholar 

  • Augustin M, Vietri J, Tian H, Gilloteau I (2017) Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol 31(8):1316–1323

    Article  CAS  PubMed  Google Scholar 

  • Avrameas S, Selmi C (2013) Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun 41:46–49

    Article  CAS  PubMed  Google Scholar 

  • Bai XF, Li HL, Shi FD, Liu JQ, Xiao BG, Van Der Meide PH et al (1998) Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin Exp Immunol 111(1):205–210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14(6):509–515

    Article  CAS  PubMed  Google Scholar 

  • Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM et al (2013) APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4 + CD25 + T cells from peripheral blood of rheumatoid arthritis patients. Int Immunopharmacol 17(4):1075–1083

    Article  PubMed  CAS  Google Scholar 

  • Berns M, Hommes DW (2016) Anti-TNF- therapies for the treatment of Crohns disease: the past, present and future. Expert Opin Investig Drugs 25:129–143

    Article  CAS  PubMed  Google Scholar 

  • Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G et al (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6(10):1167–1175

    Article  CAS  PubMed  Google Scholar 

  • Blair HA, Duggan ST (2018) Belimumab: a review in systemic lupus erythematosus. Drugs 78(3):355–366

    Article  CAS  PubMed  Google Scholar 

  • Bluestone JA, Bour-Jordan H (2012) Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol 4(11):1–23

    Article  CAS  Google Scholar 

  • Bluestone JA, Bour-Jordan H (2019) Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol 4(11):a007542

    Google Scholar 

  • Böhm M, Luger TA, Schneider M, Schwarz T, Kuhn A (2006) New insight into immunosuppression and treatment of autoimmune diseases. Clin Exp Rheumatol 24(1):S67

    PubMed  Google Scholar 

  • Brezinski EA, Dhillon JS, Armstrong AW (2015) Economic burden of psoriasis in the United States a systematic review. JAMA Dermatol 151:651–658

    Article  PubMed  Google Scholar 

  • Bucktrout SL, Bluestone JA, Ramsdell F (2018) Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med 10(1):79

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ (2016) The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas DermoSifiliogr 107(7):577–590. (English Ed)

    Article  CAS  PubMed  Google Scholar 

  • Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 72(9):3666–3670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620

    Article  PubMed  Google Scholar 

  • Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C et al (2000) Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 356(9229):545–549

    Article  CAS  PubMed  Google Scholar 

  • Chandrashekara S (2012) The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol 44(6):665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chatenoud L (2010) Immune therapy for type 1 diabetes mellituswhat is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6(3):149–157

    Article  CAS  PubMed  Google Scholar 

  • Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227–242

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10

    Article  PubMed  CAS  Google Scholar 

  • Chen AY, Chonghasawat AO, Leadholm KL (2017) Multiple sclerosis: frequency, cost, and economic burden in the United States. J Clin Neurosci 45:180–186

    Article  PubMed  Google Scholar 

  • Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415

    Article  CAS  PubMed  Google Scholar 

  • Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T et al (2014) The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73(7):1316–1322

    Article  PubMed  Google Scholar 

  • De Miguel-Luken MJ, Mansinho A, Boni V, Calvo E (2017) Immunotherapy-based combinations: current status and perspectives. Curr Opin Oncol 29(5):382–394

    Article  PubMed  CAS  Google Scholar 

  • Derfuss T, Kuhle J, Lindberg R, Kappos L (2013) Natalizumab therapy for multiple sclerosis. Semin Neurol 33(1):26–36

    Article  PubMed  Google Scholar 

  • Diabetes Prevention Trial--Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346(22):1685–1691

    Article  Google Scholar 

  • Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87(6):2095–2147

    Article  CAS  PubMed  Google Scholar 

  • Dominguez MDC, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernández MV, Torres A et al (2011) An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity 44(6):471–482

    Article  CAS  Google Scholar 

  • Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG et al (2006) CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155(1):170–181

    Article  CAS  PubMed  Google Scholar 

  • Ermann J, Fathman CG (2001) Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2(9):759–761

    Article  CAS  PubMed  Google Scholar 

  • Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435(7042):612

    Article  CAS  PubMed  Google Scholar 

  • Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res 17:321–333

    Article  PubMed  Google Scholar 

  • Fierabracci A (2011) Peptide immunotherapies in type 1 diabetes: lessons from animal models. Curr Med Chem 18(4):577–586

    Article  CAS  PubMed  Google Scholar 

  • Fife BT, Pauken KE (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 1217(1):45–59

    Article  CAS  PubMed  Google Scholar 

  • Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015–3029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ganapathy S, Vaishnavi Vedam, Vini Rajeev RA. Autoimmune disorders–immunopathogenesis and potential therapies. J Young Pharm 2017;9(1):14–22

    Google Scholar 

  • Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 353(11):1114–1123

    Article  CAS  PubMed  Google Scholar 

  • Gong Z, Pan L, Le Y, Liu Q, Zhou M, Xing W et al (2010) Glutamic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanism. Vaccine 28(24):4052–4058

    Article  CAS  PubMed  Google Scholar 

  • Grigore A, Inform A (2017) Plant phenolic compounds as immunomodulatory agents. Phenolic Compd Act London, UK IntechOpen. (8):75–98

    Google Scholar 

  • Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780

    Article  PubMed  CAS  Google Scholar 

  • Gulácsi L, Brodszky V, Baji P, Kim HU, Kim SY, Cho YY et al (2015) Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol 11:S43–S52

    Article  PubMed  Google Scholar 

  • Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E et al (2004) Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27(10):2348–2355

    Article  CAS  PubMed  Google Scholar 

  • Hartung HP (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8:28–31

    Article  PubMed  Google Scholar 

  • Hartung DM (2017) Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics 14:1018–1026

    Article  PubMed  PubMed Central  Google Scholar 

  • Hartung DM, Bourdette DN, Whitham RH (2015) The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Author response. Neurology 84(21):2185–2192

    Article  PubMed  PubMed Central  Google Scholar 

  • Hauselmann H (1998) Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Rheumatology 37(10):1110–1117

    Article  CAS  Google Scholar 

  • Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234

    Article  CAS  PubMed  Google Scholar 

  • He XS, Gershwin ME, Ansari AA (2017) Checkpoint-based immunotherapy for autoimmune diseases – opportunities and challenges. J Autoimmun 79:1–3

    Article  CAS  PubMed  Google Scholar 

  • Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297–314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hirsch DL, Ponda P (2014) Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther 4:1–11

    PubMed  PubMed Central  Google Scholar 

  • Hofmann K, Clauder AK, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 23(9):835

    Article  CAS  Google Scholar 

  • Hogquist KA, Baldwin TA, Jameson SC (2005) Central tolerance: learning self-control in the thymus. Nat Rev Immunol 5:772–782

    Article  CAS  PubMed  Google Scholar 

  • Huang Z, Yang B, Shi Y, Cai B, Li Y, Feng W et al (2012) Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol 279(1):25–29

    Article  CAS  PubMed  Google Scholar 

  • Imbach P, D’Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 317(8232):1228–1231

    Article  Google Scholar 

  • Janikashvili N, Samson M, Magen E, Chikovani T (2016) Immunotherapeutic targeting in autoimmune diseases. Mediat Inflamm 2016:2–4

    Article  Google Scholar 

  • Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389(10083):2031–2040

    Article  CAS  PubMed  Google Scholar 

  • Juryńczyk M, Walczak A, Jurewicz A, Jesionek-Kupnicka D, Szczepanik M, Selmaj K (2010) Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 68(5):593–601

    Article  PubMed  CAS  Google Scholar 

  • Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162(10):5775–5783

    Article  CAS  PubMed  Google Scholar 

  • Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P et al (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 6(10):1176–1182

    Article  CAS  PubMed  Google Scholar 

  • Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401

    Article  CAS  PubMed  Google Scholar 

  • Kil LP, De Bruijn MJW, Van Nimwegen M, Corneth OBJ, Van Hamburg JP, Dingjan GM et al (2012) Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119(16):3744–3756

    Article  CAS  PubMed  Google Scholar 

  • Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, Youn J et al (2002) Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 46(4):1109–1120

    Article  CAS  PubMed  Google Scholar 

  • Kimura A, Kishimoto T (2010) IL-6: Regulator of Treg/Th17 balance. Eur J Immunol 40:1830–1835

    Article  CAS  PubMed  Google Scholar 

  • Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J 23(8):1123–1136

    Article  Google Scholar 

  • Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL et al (2009) Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 60(11):3207–3216

    Article  CAS  PubMed  Google Scholar 

  • Lerner A, Jeremias P, Matthias T (2015) The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis 3(4):151–155

    Article  Google Scholar 

  • Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793–801

    Article  CAS  PubMed  Google Scholar 

  • Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359(18):1909–1920

    Article  CAS  PubMed  Google Scholar 

  • Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366(5):433–442

    Article  CAS  PubMed  Google Scholar 

  • Macleod MK, Anderton SM (2015) Antigen-based immunotherapy (AIT) for autoimmune and allergic disease. Curr Opin Pharmacol 23:11–16

    Article  CAS  PubMed  Google Scholar 

  • Mayer L, Kaser A, Blumberg RS (2012) Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology 143:13–17

    Article  PubMed  Google Scholar 

  • McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC (2015) T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523(7562):612–616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meacock R, Dale N, Harrison MJ (2013) The humanistic and economic burden of systemic lupus erythematosus: a systematic review. PharmacoEconomics 31:49–61

    Article  PubMed  Google Scholar 

  • Mennini FS, Marcellusi A, Gitto L, Iannone F (2017) Economic burden of rheumatoid arthritis in Italy: possible consequences on anti-citrullinated protein antibody-positive patients. Clin Drug Investig 37(4):375–386

    Article  PubMed  Google Scholar 

  • Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087

    Article  CAS  PubMed  Google Scholar 

  • Metzler B, Wraith DC (1993) Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 5(9):1159–1165

    Article  CAS  PubMed  Google Scholar 

  • Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I et al (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243–2250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miller SD, Turley DM, Podojil JR (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 7(9):665–677

    Article  CAS  PubMed  Google Scholar 

  • Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S (2003) T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice. Eur J Immunol 33:287–296

    Article  CAS  PubMed  Google Scholar 

  • Muller S, Monneaux F, Schal N, Rashkov RK, Oparanov BA, Wiesel P et al (2008) Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 58(12):3873–3883

    Article  CAS  PubMed  Google Scholar 

  • Musette P, Bouaziz JD (2018) B cell modulation strategies in autoimmune diseases: new concepts. Front Immunol 9:1–5

    Article  CAS  Google Scholar 

  • Nagler-Anderson C, Bober LA, Robinson ME, Siskind GWTG (1986) Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 83(19):7443–7446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nagy G, Huszthy PC, Fossum E, Konttinen Y, Nakken BSP (2015) Selected aspects in the pathogenesis of autoimmune diseases. Mediators Inflamm 2015

    Google Scholar 

  • Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A et al (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651):1746–1755

    Article  PubMed  CAS  Google Scholar 

  • Nipp RD, Sonet EM, Guy GP (2018) Communicating the financial burden of treatment with patients. Am Soc Clin Oncol Educ B 38:524–531

    Article  Google Scholar 

  • Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P et al (2005) Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3 + regulatory T cells. J Immunol 174(11):6993–7005

    Article  CAS  PubMed  Google Scholar 

  • Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412–419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ostrov BE (2015) Immunotherapeutic biologic agents in autoimmune and autoinflammatory diseases. Immunol Investig 44(8):777–802

    Article  CAS  Google Scholar 

  • Pers YM, Jorgensen C (2016) Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Immunotherapy 8:1091–1096

    Article  CAS  PubMed  Google Scholar 

  • Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A et al (2000) No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). Diabetologia 43(8):1000–1004

    Article  CAS  PubMed  Google Scholar 

  • Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J et al (2004) Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci 101(12):4228–4233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Puentes F, Dickhaut K, Hofstätter M, Falk K, Rötzschke O (2013) Active suppression induced by repetitive self-epitopes protects against EAE development. PLoS One 8(5):e64888

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA et al (2014) Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care 37:1392–1400

    Article  CAS  PubMed  Google Scholar 

  • Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W (2014) Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol 12(9):1494–1502

    Article  CAS  PubMed  Google Scholar 

  • Rosenblum MD, Remedios KA, Abbas AK (2015) Mechanisms of human autoimmunity. J Clin Invest 125(6):2228–2233

    Article  PubMed  PubMed Central  Google Scholar 

  • Rosman Z, Shoenfeld Y, Zandman-Goddard G (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11:88–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391

    Article  CAS  PubMed  Google Scholar 

  • Salinas GF, Braza F, Brouard S, Tak PP, Baeten D (2013) The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol 146:34–45

    Article  CAS  PubMed  Google Scholar 

  • Scalapino KJ, Daikh DI (2008) CTLA-4: A key regulatory point in the control of autoimmune disease. Immunol Rev 223:143–155

    Article  CAS  PubMed  Google Scholar 

  • Sebastiani GD, Prevete I, Iuliano A, Minisola G (2016) The importance of an early diagnosis in systemic lupus erythematosus. Isr Med Assoc J 18(3–4):212–215

    PubMed  Google Scholar 

  • Severs M, Oldenburg B, Van Bodegraven AA, Siersema PD, Mangen MJ, Initiative of Crohn’s and Colitis (2016) The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis 11(3):289–296

    Google Scholar 

  • Smilek DE, Ehlers MR, Nepom GT (2014) Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 7(5):503–513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smyth MJ, Teng MW (2018) 2018 Nobel Prize in physiology or medicine. Clin Transl Immunol 7(10):e1041

    Article  Google Scholar 

  • Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125(Suppl 2):S73–S80

    Article  PubMed  PubMed Central  Google Scholar 

  • Sugiyama H, McCormick TS, Cooper KD, Korman NJ (2008) Alefacept in the treatment of psoriasis. Clin Dermatol 26(5):503–508

    Article  PubMed  Google Scholar 

  • Tanaka Y, Mola EM (2014) IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumaband sirukumab. Ann Rheum Dis 73:1595–1597

    Article  CAS  PubMed  Google Scholar 

  • Thompson HSG, Harper N, Bevan DJ, Staines NA (1993) Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 16(3):189–199

    Article  CAS  PubMed  Google Scholar 

  • Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R et al (1996) Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2(12):1348–1353

    Article  CAS  PubMed  Google Scholar 

  • Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO (1998) Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47(6):894–899

    Article  CAS  PubMed  Google Scholar 

  • Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al (2015) Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 72(6):961–967.e5

    Google Scholar 

  • Velasquez MP, Bonifant CL, Gottschalk S (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30–38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Verazza S, Negro G, Marafon D, Consolaro A, Martini A, Ravelli A (2013) Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 31(Suppl 78):S98–S101

    PubMed  Google Scholar 

  • Viswanath D (2013) Understanding autoimmune diseases- a review. IOSR J Dent Med Sci 6(6):08–15

    Article  Google Scholar 

  • Walczak A, Siger M, Ciach A, Szczepanik M, Selmaj K (2013) Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol 70(9):1105–1109

    Article  PubMed  Google Scholar 

  • Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K et al (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (United Kingdom) 52(7):1313–1322

    Article  CAS  Google Scholar 

  • Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R (2009) No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32(11):2036–2040

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H, Yang J, Jin L, Feng J, Lu Y, Sun Y et al (2009) Immunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptides. Immunol Investig 38(8):690–703

    Article  CAS  Google Scholar 

  • Wang L, Wang FS, Chang C, Gershwin ME (2014) Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis 34(3):297–317

    Article  PubMed  CAS  Google Scholar 

  • Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369–395

    Article  CAS  PubMed  Google Scholar 

  • Warren KG, Catz I, Wucherpfennig KW (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 152(1):31–38

    Article  CAS  PubMed  Google Scholar 

  • Warrington R, Watson W, Kim HL, Antonetti FR (2011) An introduction to immunology and immunopathology. Allergy, Asthma Clin Immunol 7(S1):1–8

    Article  CAS  Google Scholar 

  • Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM et al (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259(5099):1321–1324

    Article  CAS  PubMed  Google Scholar 

  • Wherrett DK, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R et al (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378(9788):319–327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wraith DC (2017) The future of immunotherapy: a 20-year perspective. Front Immunol 8:1668

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108:1097–1104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ylisaukko-Oja T, Torvinen S, Ventola H, Schmidt S, Herrala S, Kononoff J et al (2019) Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab. Scand J Gastroenterol 14:1–7

    Google Scholar 

  • Yoshino S (1995) Antigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunization. Cell Immunol 163(1):55–58

    Article  CAS  PubMed  Google Scholar 

  • Yu C, Gershwin ME, Chang C (2014) Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 48–49:10–13

    Article  PubMed  CAS  Google Scholar 

  • Zaprutko T, Kopciuch D, Kus K, Merks P, Nowicka M, Augustyniak I et al (2017) Affordability of medicines in the European Union. PLoS One 12(2):e0172753

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhang Q, Vignali DAA (2016) Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity 44(5):1034–1051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng MK, Shih DQ, Chen GC (2017) Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol 23:1932–1943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Centre for Cell Science, Pune, India

    Aniket Mali

  2. Department of Pharmaceutics, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, University of Mumbai, Mumbai, India

    Apurva Sawant

  3. Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’s NMIMS University, Mumbai, India

    Anagha Mahadik

  4. SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, University of Mumbai, Mumbai, India

    Sujit Nair

Authors
  1. Aniket Mali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Apurva Sawant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anagha Mahadik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sujit Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sujit Nair .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutics, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India

    Sujata P. Sawarkar

  2. Department of Pharmacology, STES’s Smt. Kashibai Navale College of Pharmacy, S. P. Pune University, Pune, Maharashtra, India

    Vandana S. Nikam

  3. School of Pharmacy, Anjuman-I-Islam’s, Kalsekar Technical Campus, Mumbai, Maharashtra, India

    Shariq Syed

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mali, A., Sawant, A., Mahadik, A., Nair, S. (2021). Immunotherapy for Autoimmune Diseases. In: Sawarkar, S.P., Nikam, V.S., Syed, S. (eds) Immunotherapy – A Novel Facet of Modern Therapeutics. Springer, Singapore. https://doi.org/10.1007/978-981-15-9038-2_4

Download citation

Publish with us

Policies and ethics

Search

Navigation